Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
39.38
+1.27 (3.33%)
At close: Dec 5, 2025, 4:00 PM EST
39.98
+0.60 (1.52%)
After-hours: Dec 5, 2025, 6:51 PM EST
Zenas BioPharma Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Zenas BioPharma stock ranges from a low of $19 to a high of $55. The average analyst price target of $40 forecasts a 1.57% increase in the stock price over the next year.
Price Target: $40.00 (+1.57%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $55 | Buy | Initiates | $55 | +39.66% | Nov 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $34 → $37 | Buy | Maintains | $34 → $37 | -6.04% | Nov 13, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $27 → $46 | Strong Buy | Maintains | $27 → $46 | +16.81% | Oct 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $31 → $34 | Buy | Maintains | $31 → $34 | -13.66% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $44 | Strong Buy | Maintains | $30 → $44 | +11.73% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
42.50M
from 5.00M
Increased by 750.00%
Revenue Next Year
n/a
from 42.50M
EPS This Year
-3.77
from -11.89
EPS Next Year
-4.32
from -3.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 89.3M | n/a | ||||
| Avg | 42.5M | n/a | ||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,685.0% | - | ||||
| Avg | 750.0% | - | ||||
| Low | 96.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.31 | -3.61 | ||||
| Avg | -3.77 | -4.32 | ||||
| Low | -5.23 | -4.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.